<DOC>
	<DOCNO>NCT02610062</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability AGS67E give two dose schedule ( every three week weekly ) , subject acute myeloid leukemia ( AML ) determine safe dose future development . In addition , study ass pharmacokinetics ( PK ) , immunogenicity , antitumor activity AGS67E .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Escalating Doses AGS67E Given Monotherapy Subjects With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>The study sequentially evaluate AGS67E give 30 minute intravenous ( IV ) infusion two different schedule : every 3 week ( Q3 ) weekly 3 week . The dose escalation follow 3 + 3 design . The Data Review Team may expand dose level intermediate dose level deem safe result least one subject Composite Complete Remission ( CRc ) . An expansion cohort may enroll 15 subject .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Subject define morphologically document primary secondary AML World Health Organization ( WHO ) criterion ( 2008 ) fulfill one following : Refractory least 1 cycle induction chemotherapy Relapsed achieve remission prior therapy Patients untreated AML either disease unwilling unable undergo highdose induction/consolidation intensive chemotherapy Circulating blast &lt; 20,000 ( cytoreduction hydroxyurea allow ) Eastern Cooperative Oncology Group performance score ( ECOG ) 0 , 1 2 Renal function : serum creatinine ≤ 2.0 mg/dL estimate creatinine clearance ≥ 30 mL/min CockcroftGault equation Direct bilirubin ≤ 1.5 x upper limit normal ( ULN ) , albumin ≥ 2.5 g/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Negative pregnancy test woman child bear potential Sexually active fertile subject , partner , must agree use medically accept doublebarrier method contraception ( e.g. , barrier method , include male condom , female condom , diaphragm spermicidal gel ) study least 6 week termination study therapy Acute promyelocytic leukemia Preexisting sensory motor neuropathy Grade ≥ 2 baseline Small molecule therapy , radiotherapy , immunotherapy , monoclonal antibody , chemotherapy within 14 day first dose study drug , exception hydroxyurea Pgp inducers/inhibitors strong CYP3A inhibitor within 14 day first dose drug , exception antibiotics/ antifungal use prophylaxis and/or supportive care Any Grade ≥ 2 persistent nonhematological toxicity relate allotransplant GraftVersusHost Disease ( GVHD ) therapy within 6 week first dose study drug ; low dose steroid ( &lt; 10mg ) allow Known current central nervous system ( CNS ) disease Active angina clinically significant cardiac disease within 6 month first dose study drug , include myocardial infarction , unstable angina , Grade 2 great peripheral vascular disease , congestive heart failure , uncontrolled hypertension , arrhythmias control outpatient medication Clinical Disseminated Intravascular Coagulation ( DIC ) Known human immunodeficiency virus ( HIV ) positive AIDS Positive Hepatitis B surface antigen test Decompensated liver disease evidence clinically significant ascites refractory diuretic therapy , hepatic encephalopathy , coagulopathy Active infection require treatment ≤7 day first dose study drug . Controlled infection ( i.e . 3 negative culture complete antibiotic and/or stable fungal infection therapy &gt; 14 day ) allow Known sensitivity component investigational product AGS67E : AGS67E LHistidine αtrehalose dihydrate polysorbate 20 Pregnant lactate woman Condition situation may put subject significant risk , may confound study result , may interfere significantly subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>